Now showing items 1-13 of 13

    • A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. 

      Prat, A; Lluch, A; Turnbull, AK; Dunbier, AK; Calvo, L; Albanell, J; de la Haba-Rodríguez, J; Arcusa, A; Chacón, JI; Sánchez-Rovira, P; Plazaola, A; Muñoz, M; Paré, L; Parker, JS; Ribelles, N; Jimenez, B; Bin Aiderus, AA; Caballero, R; Adamo, B; Dowsett, M; Carrasco, E; Martín, M; Dixon, JM; Perou, CM; Alba, E (2017-06)
      <b>Purpose:</b> Hormone receptor-positive (HR<sup>+</sup>) breast cancer is clinically and biologically heterogeneous, and subgroups with different prognostic and treatment sensitivities need to be identified.<b>Experimental ...
    • ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942. 

      Sava, GP; Fan, H; Fisher, RA; Lusvarghi, S; Pancholi, S; Ambudkar, SV; Martin, L-A; Charles Coombes, R; Buluwela, L; Ali, S (2020-01)
      The CDK7 inhibitors (CDK7i) ICEC0942 and THZ1, are promising new cancer therapeutics. Resistance to targeted drugs frequently compromises cancer treatment. We sought to identify mechanisms by which cancer cells may become ...
    • Comparison of protein expression between formalin-fixed core-cut biopsies and surgical excision specimens using a novel multiplex approach. 

      Leal, MF; Haynes, BP; MacNeill, FA; Dodson, A; Dowsett, M (2019-06)
      Purpose We evaluated whether multiplex protein quantification using antibody bar-coding with photocleavable oligonucleotides (NanoString) can be applied to evaluate protein expression in breast cancer FFPE specimens. We ...
    • DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. 

      Touat, M; Sourisseau, T; Dorvault, N; Chabanon, RM; Garrido, M; Morel, D; Krastev, DB; Bigot, L; Adam, J; Frankum, JR; Durand, S; Pontoizeau, C; Souquère, S; Kuo, M-S; Sauvaigo, S; Mardakheh, F; Sarasin, A; Olaussen, KA; Friboulet, L; Bouillaud, F; Pierron, G; Ashworth, A; Lombès, A; Lord, CJ; Soria, J-C; Postel-Vinay, S (2018-04)
      Synthetic lethality is an efficient mechanism-based approach to selectively target DNA repair defects. Excision repair cross-complementation group 1 (ERCC1) deficiency is frequently found in non-small-cell lung cancer ...
    • Endosialin-Expressing Pericytes Promote Metastatic Dissemination. 

      Viski, C; König, C; Kijewska, M; Mogler, C; Isacke, CM; Augustin, HG (2016-09)
      Metastasis is a multistep process that is critically dependent on the interaction of metastasizing tumor cells with cells in the local microenvironment. Within this tumor stroma, vessel-associated pericytes and myofibroblasts ...
    • Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. 

      Xiao, T; Li, W; Wang, X; Xu, H; Yang, J; Wu, Q; Huang, Y; Geradts, J; Jiang, P; Fei, T; Chi, D; Zang, C; Liao, Q; Rennhack, J; Andrechek, E; Li, N; Detre, S; Dowsett, M; Jeselsohn, RM; Liu, XS; Brown, M (2018-07-09)
      Endocrine therapy resistance invariably develops in advanced estrogen receptor-positive (ER+) breast cancer, but the underlying mechanisms are largely unknown. We have identified C-terminal SRC kinase (CSK) as a critical ...
    • Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. 

      Lawler, K; Papouli, E; Naceur-Lombardelli, C; Mera, A; Ougham, K; Tutt, A; Kimbung, S; Hedenfalk, I; Zhan, J; Zhang, H; Buus, R; Dowsett, M; Ng, T; Pinder, SE; Parker, P; Holmberg, L; Gillett, CE; Grigoriadis, A; Purushotham, A (2017-10-13)
      Metastases from primary breast cancers can involve single or multiple organs at metastatic disease diagnosis. Molecular risk factors for particular patterns of metastastic spread in a clinical population are limited.A ...
    • Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. 

      López-Knowles, E; Gao, Q; Cheang, MCU; Morden, J; Parker, J; Martin, L-A; Pinhel, I; McNeill, F; Hills, M; Detre, S; Afentakis, M; Zabaglo, L; Dodson, A; Skene, A; Holcombe, C; Robertson, J; Smith, I; Bliss, JM; Dowsett, M; POETIC trialists (2016-04)
      Background Gene expression is widely used for the characterisation of breast cancers. Variability due to tissue heterogeneity or measurement error or systematic change due to peri-surgical procedures can affect measurements ...
    • Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. 

      Dalton, WB; Helmenstine, E; Walsh, N; Gondek, LP; Kelkar, DS; Read, A; Natrajan, R; Christenson, ES; Roman, B; Das, S; Zhao, L; Leone, RD; Shinn, D; Groginski, T; Madugundu, AK; Patil, A; Zabransky, DJ; Medford, A; Lee, J; Cole, AJ; Rosen, M; Thakar, M; Ambinder, A; Donaldson, J; DeZern, AE; Cravero, K; Chu, D; Madero-Marroquin, R; Pandey, A; Hurley, PJ; Lauring, J; Park, BH (2019-08-08)
      Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are ...
    • Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. 

      Cristofanilli, M; DeMichele, A; Giorgetti, C; Turner, NC; Slamon, DJ; Im, S-A; Masuda, N; Verma, S; Loi, S; Colleoni, M; Theall, KP; Huang, X; Liu, Y; Bartlett, CH (2018-11)
      Background The addition of palbociclib to fulvestrant improved clinical outcomes over placebo-fulvestrant in endocrine-pretreated metastatic breast cancer (MBC) patients in PALOMA-3. Here, we examined factors predictive ...
    • Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. 

      Hurvitz, SA; Quek, RGW; Turner, NC; Telli, ML; Rugo, HS; Mailliez, A; Ettl, J; Grischke, E; Mina, LA; Balmaña, J; Fasching, PA; Bhattacharyya, H; Hannah, AL; Robson, ME; Wardley, AM (2018-11)
      Background Talazoparib (1 mg/day) exhibited promising efficacy and safety in patients with advanced breast cancer during ABRAZO (NCT02034916); this study evaluated patient-reported outcomes (PROs).Patients and methods ...
    • Shared heritability and functional enrichment across six solid cancers. 

      Jiang, X; Finucane, HK; Schumacher, FR; Schmit, SL; Tyrer, JP; Han, Y; Michailidou, K; Lesseur, C; Kuchenbaecker, KB; Dennis, J; Conti, DV; Casey, G; Gaudet, MM; Huyghe, JR; Albanes, D; Aldrich, MC; Andrew, AS; Andrulis, IL; Anton-Culver, H; Antoniou, AC; Antonenkova, NN; Arnold, SM; Aronson, KJ; Arun, BK; Bandera, EV; Barkardottir, RB; Barnes, DR; Batra, J; Beckmann, MW; Benitez, J; Benlloch, S; Berchuck, A; Berndt, SI; Bickeböller, H; Bien, SA; Blomqvist, C; Boccia, S; Bogdanova, NV; Bojesen, SE; Bolla, MK; Brauch, H; Brenner, H; Brenton, JD; Brook, MN; Brunet, J; Brunnström, H; Buchanan, DD; Burwinkel, B; Butzow, R; Cadoni, G; Caldés, T; Caligo, MA; Campbell, I; Campbell, PT; Cancel-Tassin, G; Cannon-Albright, L; Campa, D; Caporaso, N; Carvalho, AL; Chan, AT; Chang-Claude, J; Chanock, SJ; Chen, C; Christiani, DC; Claes, KBM; Claessens, F; Clements, J; Collée, JM; Correa, MC; Couch, FJ; Cox, A; Cunningham, JM; Cybulski, C; Czene, K; Daly, MB; deFazio, A; Devilee, P; Diez, O; Gago-Dominguez, M; Donovan, JL; Dörk, T; Duell, EJ; Dunning, AM; Dwek, M; Eccles, DM; Edlund, CK; Edwards, DRV; Ellberg, C; Evans, DG; Fasching, PA; Ferris, RL; Liloglou, T; Figueiredo, JC; Fletcher, O; Fortner, RT; Fostira, F; Franceschi, S; Friedman, E; Gallinger, SJ; Ganz, PA; Garber, J; García-Sáenz, JA; Gayther, SA; Giles, GG; Godwin, AK; Goldberg, MS; Goldgar, DE; Goode, EL; Goodman, MT; Goodman, G; Grankvist, K; Greene, MH; Gronberg, H; Gronwald, J; Guénel, P; Håkansson, N; Hall, P; Hamann, U; Hamdy, FC; Hamilton, RJ; Hampe, J; Haugen, A; Heitz, F; Herrero, R; Hillemanns, P; Hoffmeister, M; Høgdall, E; Hong, Y-C; Hopper, JL; Houlston, R; Hulick, PJ; Hunter, DJ; Huntsman, DG; Idos, G; Imyanitov, EN; Ingles, SA; Isaacs, C; Jakubowska, A; James, P; Jenkins, MA; Johansson, M; Johansson, M; John, EM; Joshi, AD; Kaneva, R; Karlan, BY; Kelemen, LE; Kühl, T; Khaw, K-T; Khusnutdinova, E; Kibel, AS; Kiemeney, LA; Kim, J; Kjaer, SK; Knight, JA; Kogevinas, M; Kote-Jarai, Z; Koutros, S; Kristensen, VN; Kupryjanczyk, J; Lacko, M; Lam, S; Lambrechts, D; Landi, MT; Lazarus, P; Le, ND; Lee, E; Lejbkowicz, F; Lenz, H-J; Leslie, G; Lessel, D; Lester, J; Levine, DA; Li, L; Li, CI; Lindblom, A; Lindor, NM; Liu, G; Loupakis, F; Lubiński, J; Maehle, L; Maier, C; Mannermaa, A; Marchand, LL; Margolin, S; May, T; McGuffog, L; Meindl, A; Middha, P; Miller, A; Milne, RL; MacInnis, RJ; Modugno, F; Montagna, M; Moreno, V; Moysich, KB; Mucci, L; Muir, K; Mulligan, AM; Nathanson, KL; Neal, DE; Ness, AR; Neuhausen, SL; Nevanlinna, H; Newcomb, PA; Newcomb, LF; Nielsen, FC; Nikitina-Zake, L; Nordestgaard, BG; Nussbaum, RL; Offit, K; Olah, E; Olama, AAA; Olopade, OI; Olshan, AF; Olsson, H; Osorio, A; Pandha, H; Park, JY; Pashayan, N; Parsons, MT; Pejovic, T; Penney, KL; Peters, WHM; Phelan, CM; Phipps, AI; Plaseska-Karanfilska, D; Pring, M; Prokofyeva, D; Radice, P; Stefansson, K; Ramus, SJ; Raskin, L; Rennert, G; Rennert, HS; van Rensburg, EJ; Riggan, MJ; Risch, HA; Risch, A; Roobol, MJ; Rosenstein, BS; Rossing, MA; De Ruyck, K; Saloustros, E; Sandler, DP; Sawyer, EJ; Schabath, MB; Schleutker, J; Schmidt, MK; Setiawan, VW; Shen, H; Siegel, EM; Sieh, W; Singer, CF; Slattery, ML; Sorensen, KD; Southey, MC; Spurdle, AB; Stanford, JL; Stevens, VL; Stintzing, S; Stone, J; Sundfeldt, K; Sutphen, R; Swerdlow, AJ; Tajara, EH; Tangen, CM; Tardon, A; Taylor, JA; Teare, MD; Teixeira, MR; Terry, MB; Terry, KL; Thibodeau, SN; Thomassen, M; Bjørge, L; Tischkowitz, M; Toland, AE; Torres, D; Townsend, PA; Travis, RC; Tung, N; Tworoger, SS; Ulrich, CM; Usmani, N; Vachon, CM; Van Nieuwenhuysen, E; Vega, A; Aguado-Barrera, ME; Wang, Q; Webb, PM; Weinberg, CR; Weinstein, S; Weissler, MC; Weitzel, JN; West, CML; White, E; Whittemore, AS; Wichmann, H-E; Wiklund, F; Winqvist, R; Wolk, A; Woll, P; Woods, M; Wu, AH; Wu, X; Yannoukakos, D; Zheng, W; Zienolddiny, S; Ziogas, A; Zorn, KK; Lane, JM; Saxena, R; Thomas, D; Hung, RJ; Diergaarde, B; McKay, J; Peters, U; Hsu, L; García-Closas, M; Eeles, RA; Chenevix-Trench, G; Brennan, PJ; Haiman, CA; Simard, J; Easton, DF; Gruber, SB; Pharoah, PDP; Price, AL; Pasaniuc, B; Amos, CI; Kraft, P; Lindström, S (2019-01-25)
      Quantifying the genetic correlation between cancers can provide important insights into the mechanisms driving cancer etiology. Using genome-wide association study summary statistics across six cancer types based on a total ...
    • The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer. 

      Barry, P; Vatsiou, A; Spiteri, I; Nichol, D; Cresswell, GD; Acar, A; Trahearn, N; Hrebien, S; Garcia-Murillas, I; Chkhaidze, K; Ermini, L; Huntingford, IS; Cottom, H; Zabaglo, L; Koelble, K; Khalique, S; Rusby, JE; Muscara, F; Dowsett, M; Maley, CC; Natrajan, R; Yuan, Y; Schiavon, G; Turner, N; Sottoriva, A (2018-10)
      <b>Purpose:</b> The most significant prognostic factor in early breast cancer is lymph node involvement. This stage between localized and systemic disease is key to understanding breast cancer progression; however, our ...